Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis
  • CME
  • CE

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Released: December 7, 2020 Expiration: December 6, 2021
Start Activity
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Gilead Sciences
Stanley B. Cohen, MD
Sheetal Desai, MD, MSEd
Eric M. Ruderman, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Engage patients in describing the range of their RA burden, their expectations of disease control with therapy, and their treatment preferences
  • Summarize key findings from the latest clinical trials of new and emerging targeted therapies for patients with active RA, including those who have who have failed other DMARDs
  • Detail JAK selectivity as it relates to current and emerging JAK inhibitor drugs and safety outcomes to date for individual agents

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Pfizer and funds for research support from AbbVie, Gilead Sciences, Lilly, and Pfizer.
Sheetal Desai, MD, MSEd

Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Sheetal Desai, MD, MSEd, has disclosed that she has received consulting fees and fees for non-CME/CE services from Janssen.
Eric M. Ruderman, MD

Professor
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Eric M. Ruderman, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, and Selecta.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for rheumatology specialists and registered nurses attending ACR/ARP Annual Meeting as well as other healthcare providers who work in a rheumatology practice or treat patients with RA.

Goal

The goal of this activity is to improve clinician competence in considering the patient perspective and in applying efficacy and safety data from recent studies of new and emerging targeted DMARD therapies when considering treatment options for patients with active RA.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 07, 2020, through December 06, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Treat-to-Target in RA: Using a Shared Decision-Making Approach
  • CME
  • CE

Loading...
Stanley B. Cohen, MD
Sheetal Desai, MD, MSEd
Eric M. Ruderman, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Released: December 7, 2020 Expiration: December 6, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

Assessment of depth, rapidity of response of abrocitinib and dupilumab in patients with moderate to severe AD in JADE COMPARE using stringent endpoints: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 15, 2021

Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 11, 2021

Analysis of efficacy of oral azoles as a potential treatment for dupilumab facial redness: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 10, 2021

Expert commentary from Dr. Bruce Sands on therapeutic drug monitoring in IBD, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: June 3, 2021

Video Chapters


Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue